Concepts (246)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Depressive Disorder, Major | 29 | 2022 | 88 | 4.630 |
Why?
|
| Antidepressive Agents | 26 | 2023 | 88 | 3.140 |
Why?
|
| Depressive Disorder | 30 | 2007 | 163 | 2.670 |
Why?
|
| Bipolar Disorder | 14 | 2017 | 99 | 2.010 |
Why?
|
| Depressive Disorder, Treatment-Resistant | 6 | 2023 | 9 | 1.850 |
Why?
|
| Antidepressive Agents, Second-Generation | 13 | 2010 | 28 | 1.250 |
Why?
|
| Psychiatric Status Rating Scales | 26 | 2020 | 267 | 1.080 |
Why?
|
| Ketamine | 2 | 2023 | 23 | 0.910 |
Why?
|
| Antipsychotic Agents | 9 | 2016 | 50 | 0.880 |
Why?
|
| Fluoxetine | 15 | 2009 | 34 | 0.880 |
Why?
|
| Secondary Prevention | 16 | 2020 | 48 | 0.800 |
Why?
|
| Triazoles | 7 | 2003 | 28 | 0.780 |
Why?
|
| Double-Blind Method | 29 | 2020 | 373 | 0.780 |
Why?
|
| Treatment Outcome | 34 | 2022 | 2939 | 0.720 |
Why?
|
| Vagus Nerve Stimulation | 2 | 2022 | 8 | 0.700 |
Why?
|
| Tetrahydrofolates | 3 | 2016 | 3 | 0.700 |
Why?
|
| Humans | 78 | 2023 | 22912 | 0.690 |
Why?
|
| Depression | 7 | 2022 | 368 | 0.690 |
Why?
|
| Valproic Acid | 5 | 2008 | 13 | 0.680 |
Why?
|
| Substance Withdrawal Syndrome | 6 | 2003 | 34 | 0.660 |
Why?
|
| Adult | 45 | 2019 | 6924 | 0.590 |
Why?
|
| Cyclohexanols | 9 | 2010 | 18 | 0.580 |
Why?
|
| Male | 56 | 2020 | 12459 | 0.570 |
Why?
|
| Drug Therapy, Combination | 15 | 2019 | 162 | 0.560 |
Why?
|
| Female | 54 | 2020 | 12939 | 0.540 |
Why?
|
| Suicidal Ideation | 1 | 2017 | 7 | 0.520 |
Why?
|
| Sexual Dysfunctions, Psychological | 5 | 2005 | 11 | 0.510 |
Why?
|
| Middle Aged | 36 | 2020 | 7911 | 0.510 |
Why?
|
| Piperazines | 11 | 2015 | 82 | 0.460 |
Why?
|
| Electroconvulsive Therapy | 3 | 2017 | 16 | 0.430 |
Why?
|
| Folic Acid | 2 | 2016 | 21 | 0.380 |
Why?
|
| Anxiety Disorders | 4 | 2002 | 163 | 0.370 |
Why?
|
| Drug Administration Schedule | 15 | 2007 | 153 | 0.350 |
Why?
|
| Acetamides | 1 | 2010 | 2 | 0.320 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2020 | 313 | 0.320 |
Why?
|
| Sexual Behavior | 2 | 2002 | 46 | 0.310 |
Why?
|
| Pirenzepine | 3 | 2003 | 5 | 0.290 |
Why?
|
| Adolescent | 13 | 2015 | 1881 | 0.290 |
Why?
|
| Acute Disease | 7 | 2013 | 163 | 0.260 |
Why?
|
| Personality Inventory | 5 | 2012 | 68 | 0.260 |
Why?
|
| Aged | 17 | 2016 | 7442 | 0.260 |
Why?
|
| Antimanic Agents | 1 | 2006 | 7 | 0.250 |
Why?
|
| Social Adjustment | 2 | 2010 | 20 | 0.240 |
Why?
|
| Administration, Intranasal | 2 | 2023 | 26 | 0.230 |
Why?
|
| Sertraline | 5 | 2006 | 24 | 0.230 |
Why?
|
| Chronic Disease | 6 | 2017 | 375 | 0.230 |
Why?
|
| Surveys and Questionnaires | 5 | 2015 | 1021 | 0.220 |
Why?
|
| Prospective Studies | 4 | 2017 | 1493 | 0.220 |
Why?
|
| Remission Induction | 5 | 2020 | 89 | 0.210 |
Why?
|
| Venlafaxine Hydrochloride | 9 | 2010 | 17 | 0.210 |
Why?
|
| Obsessive-Compulsive Disorder | 4 | 2006 | 15 | 0.210 |
Why?
|
| Placebos | 7 | 2006 | 63 | 0.210 |
Why?
|
| Obesity | 3 | 2015 | 288 | 0.200 |
Why?
|
| Follow-Up Studies | 7 | 2017 | 1409 | 0.200 |
Why?
|
| Recurrence | 5 | 2016 | 268 | 0.190 |
Why?
|
| Young Adult | 5 | 2016 | 1652 | 0.190 |
Why?
|
| Ambulatory Care | 7 | 2008 | 66 | 0.190 |
Why?
|
| Combined Modality Therapy | 6 | 2020 | 294 | 0.170 |
Why?
|
| Quality of Life | 5 | 2010 | 557 | 0.170 |
Why?
|
| Receptors, Opioid, kappa | 1 | 2020 | 2 | 0.160 |
Why?
|
| Pyrrolidines | 1 | 2020 | 11 | 0.160 |
Why?
|
| Narcotic Antagonists | 1 | 2020 | 13 | 0.160 |
Why?
|
| Benzamides | 1 | 2020 | 13 | 0.160 |
Why?
|
| Patient Compliance | 5 | 2007 | 145 | 0.150 |
Why?
|
| Severity of Illness Index | 6 | 2007 | 801 | 0.140 |
Why?
|
| Psychotic Disorders | 2 | 2001 | 29 | 0.140 |
Why?
|
| Long-Term Care | 2 | 2016 | 56 | 0.140 |
Why?
|
| Thiazoles | 2 | 2012 | 15 | 0.140 |
Why?
|
| Antidepressive Agents, Tricyclic | 3 | 2004 | 15 | 0.140 |
Why?
|
| C-Reactive Protein | 2 | 2015 | 92 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2011 | 243 | 0.130 |
Why?
|
| Comorbidity | 6 | 2015 | 426 | 0.130 |
Why?
|
| Phenethylamines | 1 | 2016 | 1 | 0.130 |
Why?
|
| Pyridines | 1 | 2016 | 27 | 0.130 |
Why?
|
| Psychometrics | 5 | 2012 | 176 | 0.120 |
Why?
|
| Registries | 1 | 2017 | 173 | 0.120 |
Why?
|
| Glutamates | 1 | 2015 | 7 | 0.120 |
Why?
|
| Serotonin | 2 | 1997 | 22 | 0.120 |
Why?
|
| Dizziness | 4 | 2007 | 17 | 0.120 |
Why?
|
| Sexual Dysfunction, Physiological | 2 | 2007 | 4 | 0.110 |
Why?
|
| Hypericum | 2 | 2005 | 3 | 0.110 |
Why?
|
| Paroxetine | 4 | 2007 | 14 | 0.110 |
Why?
|
| Phytotherapy | 2 | 2005 | 11 | 0.110 |
Why?
|
| Sulfides | 1 | 2015 | 10 | 0.110 |
Why?
|
| Anti-Anxiety Agents | 1 | 2015 | 38 | 0.110 |
Why?
|
| S-Adenosylhomocysteine | 1 | 2014 | 1 | 0.110 |
Why?
|
| Aldehydes | 1 | 2014 | 2 | 0.110 |
Why?
|
| S-Adenosylmethionine | 1 | 2014 | 5 | 0.110 |
Why?
|
| Administration, Oral | 2 | 2019 | 96 | 0.110 |
Why?
|
| Inflammation | 1 | 2015 | 227 | 0.100 |
Why?
|
| Vagus Nerve | 2 | 2022 | 14 | 0.100 |
Why?
|
| Diagnosis, Differential | 2 | 2007 | 311 | 0.100 |
Why?
|
| Nausea | 3 | 1999 | 24 | 0.100 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 3 | 2000 | 103 | 0.100 |
Why?
|
| Anticonvulsants | 2 | 2003 | 51 | 0.100 |
Why?
|
| Hypertension | 2 | 2007 | 163 | 0.100 |
Why?
|
| Tranylcypromine | 1 | 1991 | 2 | 0.090 |
Why?
|
| Reproducibility of Results | 4 | 2005 | 592 | 0.090 |
Why?
|
| Prevalence | 1 | 2013 | 376 | 0.090 |
Why?
|
| Multicenter Studies as Topic | 1 | 2011 | 40 | 0.090 |
Why?
|
| Patient Education as Topic | 3 | 2003 | 121 | 0.090 |
Why?
|
| Headache | 3 | 2007 | 36 | 0.090 |
Why?
|
| Orgasm | 1 | 1991 | 9 | 0.090 |
Why?
|
| Fever | 1 | 1991 | 32 | 0.080 |
Why?
|
| Attitude to Health | 2 | 2002 | 90 | 0.080 |
Why?
|
| Patient Selection | 1 | 2011 | 167 | 0.080 |
Why?
|
| Rhabdomyolysis | 1 | 2010 | 5 | 0.080 |
Why?
|
| Duloxetine Hydrochloride | 2 | 2015 | 9 | 0.080 |
Why?
|
| Choice Behavior | 1 | 2010 | 40 | 0.080 |
Why?
|
| Electroencephalography | 1 | 2010 | 70 | 0.080 |
Why?
|
| Cognition Disorders | 1 | 2015 | 692 | 0.080 |
Why?
|
| Tachyphylaxis | 1 | 2009 | 1 | 0.070 |
Why?
|
| Benzodiazepines | 3 | 2003 | 45 | 0.070 |
Why?
|
| Delayed-Action Preparations | 4 | 2010 | 28 | 0.070 |
Why?
|
| Sleep Stages | 2 | 1999 | 19 | 0.070 |
Why?
|
| Ribavirin | 1 | 2007 | 9 | 0.070 |
Why?
|
| 1-Naphthylamine | 2 | 1997 | 4 | 0.070 |
Why?
|
| Interferon-alpha | 1 | 2007 | 30 | 0.070 |
Why?
|
| Half-Life | 2 | 1997 | 10 | 0.060 |
Why?
|
| Serotonin Antagonists | 2 | 2001 | 8 | 0.060 |
Why?
|
| Syndrome | 2 | 1997 | 68 | 0.060 |
Why?
|
| Analysis of Variance | 4 | 2010 | 227 | 0.060 |
Why?
|
| Hepatitis C, Chronic | 1 | 2007 | 42 | 0.060 |
Why?
|
| Antiviral Agents | 1 | 2007 | 66 | 0.060 |
Why?
|
| Adrenergic Uptake Inhibitors | 2 | 2004 | 6 | 0.060 |
Why?
|
| Substance-Related Disorders | 1 | 2007 | 87 | 0.060 |
Why?
|
| Retrospective Studies | 4 | 2007 | 2985 | 0.060 |
Why?
|
| Weight Gain | 3 | 2001 | 61 | 0.060 |
Why?
|
| Electric Stimulation Therapy | 1 | 2005 | 39 | 0.060 |
Why?
|
| Sex Factors | 2 | 2005 | 387 | 0.060 |
Why?
|
| Thiophenes | 1 | 2004 | 11 | 0.050 |
Why?
|
| Psychotherapy | 1 | 2003 | 38 | 0.050 |
Why?
|
| Health Status | 3 | 2003 | 200 | 0.050 |
Why?
|
| Morpholines | 1 | 2003 | 12 | 0.050 |
Why?
|
| Drug Tolerance | 1 | 2002 | 6 | 0.050 |
Why?
|
| Body Weight | 2 | 2002 | 129 | 0.050 |
Why?
|
| Patient Care Planning | 1 | 2003 | 32 | 0.050 |
Why?
|
| Biomarkers | 2 | 2015 | 474 | 0.050 |
Why?
|
| Personal Satisfaction | 1 | 2002 | 39 | 0.050 |
Why?
|
| Drug Interactions | 2 | 1991 | 35 | 0.040 |
Why?
|
| Mianserin | 1 | 2001 | 8 | 0.040 |
Why?
|
| Buspirone | 1 | 2001 | 4 | 0.040 |
Why?
|
| Bupropion | 1 | 2001 | 6 | 0.040 |
Why?
|
| Sildenafil Citrate | 1 | 2001 | 10 | 0.040 |
Why?
|
| Sulfones | 1 | 2001 | 20 | 0.040 |
Why?
|
| Psychomotor Agitation | 1 | 2001 | 10 | 0.040 |
Why?
|
| Sexuality | 1 | 2001 | 14 | 0.040 |
Why?
|
| Telephone | 1 | 2000 | 23 | 0.040 |
Why?
|
| Central Nervous System Stimulants | 1 | 2001 | 39 | 0.040 |
Why?
|
| Self Disclosure | 1 | 2000 | 6 | 0.040 |
Why?
|
| Purines | 1 | 2001 | 41 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2002 | 234 | 0.040 |
Why?
|
| Asthenia | 1 | 2000 | 1 | 0.040 |
Why?
|
| Desipramine | 1 | 2000 | 3 | 0.040 |
Why?
|
| Feeding and Eating Disorders | 1 | 2000 | 10 | 0.040 |
Why?
|
| Nasal Sprays | 1 | 2019 | 1 | 0.040 |
Why?
|
| Behavior Therapy | 1 | 2000 | 85 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2000 | 442 | 0.040 |
Why?
|
| Anxiety | 1 | 1999 | 143 | 0.040 |
Why?
|
| Prognosis | 1 | 2000 | 728 | 0.030 |
Why?
|
| Drug Synergism | 2 | 1995 | 38 | 0.030 |
Why?
|
| Time Factors | 3 | 2010 | 1257 | 0.030 |
Why?
|
| Fluvoxamine | 1 | 1997 | 2 | 0.030 |
Why?
|
| MEDLINE | 1 | 1997 | 5 | 0.030 |
Why?
|
| Sensation Disorders | 1 | 1997 | 9 | 0.030 |
Why?
|
| Abbreviations as Topic | 1 | 1997 | 1 | 0.030 |
Why?
|
| Paresthesia | 1 | 1997 | 2 | 0.030 |
Why?
|
| Receptors, Serotonin | 1 | 1997 | 12 | 0.030 |
Why?
|
| Treatment Refusal | 1 | 1997 | 10 | 0.030 |
Why?
|
| Neurotransmitter Agents | 1 | 1997 | 13 | 0.030 |
Why?
|
| Norepinephrine | 1 | 1997 | 28 | 0.030 |
Why?
|
| Life Change Events | 1 | 1997 | 33 | 0.030 |
Why?
|
| Medical History Taking | 1 | 1997 | 24 | 0.030 |
Why?
|
| Medical Records | 1 | 1997 | 28 | 0.030 |
Why?
|
| Quetiapine Fumarate | 1 | 2016 | 3 | 0.030 |
Why?
|
| Down-Regulation | 1 | 1997 | 87 | 0.030 |
Why?
|
| Triazines | 1 | 2016 | 11 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 1997 | 190 | 0.030 |
Why?
|
| Imipramine | 1 | 1996 | 10 | 0.030 |
Why?
|
| Family Practice | 1 | 1996 | 13 | 0.030 |
Why?
|
| Community Mental Health Services | 1 | 1996 | 15 | 0.030 |
Why?
|
| Primary Health Care | 1 | 1997 | 73 | 0.030 |
Why?
|
| Infant | 1 | 1997 | 483 | 0.030 |
Why?
|
| Drug Resistance | 2 | 2006 | 45 | 0.030 |
Why?
|
| Adiponectin | 1 | 2015 | 10 | 0.030 |
Why?
|
| Mental Disorders | 1 | 1997 | 134 | 0.030 |
Why?
|
| Leptin | 1 | 2015 | 18 | 0.030 |
Why?
|
| Heterocyclic Compounds | 1 | 1995 | 6 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 1997 | 537 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2015 | 70 | 0.030 |
Why?
|
| Plant Extracts | 2 | 2005 | 13 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 1995 | 28 | 0.030 |
Why?
|
| Affect | 1 | 1995 | 57 | 0.030 |
Why?
|
| Incidence | 1 | 1997 | 624 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2015 | 163 | 0.030 |
Why?
|
| Phobic Disorders | 1 | 1995 | 64 | 0.030 |
Why?
|
| Panic Disorder | 1 | 1995 | 133 | 0.030 |
Why?
|
| Multiple Sclerosis | 1 | 1995 | 77 | 0.030 |
Why?
|
| Carbamazepine | 1 | 1993 | 4 | 0.030 |
Why?
|
| Lithium | 1 | 1993 | 19 | 0.030 |
Why?
|
| Genotype | 1 | 2014 | 248 | 0.030 |
Why?
|
| Child | 1 | 1997 | 1157 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2012 | 80 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2015 | 865 | 0.020 |
Why?
|
| Amitriptyline | 1 | 1991 | 3 | 0.020 |
Why?
|
| Sympathomimetics | 1 | 1991 | 5 | 0.020 |
Why?
|
| Pemoline | 1 | 1991 | 1 | 0.020 |
Why?
|
| Dextroamphetamine | 1 | 1991 | 2 | 0.020 |
Why?
|
| Risk Factors | 1 | 1997 | 1971 | 0.020 |
Why?
|
| Monoamine Oxidase Inhibitors | 1 | 1991 | 16 | 0.020 |
Why?
|
| Iatrogenic Disease | 1 | 1991 | 22 | 0.020 |
Why?
|
| Drugs, Investigational | 1 | 1990 | 4 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2010 | 87 | 0.020 |
Why?
|
| Hospitalization | 1 | 1991 | 286 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 168 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 2007 | 18 | 0.020 |
Why?
|
| Respiratory Tract Infections | 1 | 2007 | 23 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2007 | 26 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2010 | 1046 | 0.020 |
Why?
|
| Outpatients | 1 | 2007 | 56 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2006 | 124 | 0.020 |
Why?
|
| Endpoint Determination | 1 | 2005 | 22 | 0.010 |
Why?
|
| Mood Disorders | 1 | 2005 | 23 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 2007 | 207 | 0.010 |
Why?
|
| Reference Values | 1 | 2005 | 169 | 0.010 |
Why?
|
| United States | 1 | 2010 | 1765 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2005 | 479 | 0.010 |
Why?
|
| Eligibility Determination | 1 | 2003 | 3 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2003 | 64 | 0.010 |
Why?
|
| Health Services | 1 | 2003 | 6 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2003 | 226 | 0.010 |
Why?
|
| Health Care Costs | 1 | 2003 | 61 | 0.010 |
Why?
|
| Priapism | 1 | 2002 | 10 | 0.010 |
Why?
|
| Suicide | 1 | 2002 | 12 | 0.010 |
Why?
|
| Seizures | 1 | 2002 | 62 | 0.010 |
Why?
|
| Patient Dropouts | 1 | 2001 | 24 | 0.010 |
Why?
|
| Injections, Intramuscular | 1 | 2001 | 8 | 0.010 |
Why?
|
| Schizophrenic Psychology | 1 | 2001 | 13 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2001 | 126 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2001 | 58 | 0.010 |
Why?
|
| Schizophrenia | 1 | 2001 | 46 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2003 | 257 | 0.010 |
Why?
|
| Age Factors | 1 | 2002 | 637 | 0.010 |
Why?
|
| Appetite | 1 | 1999 | 4 | 0.010 |
Why?
|
| Weight Loss | 1 | 1999 | 121 | 0.010 |
Why?
|
| Body Mass Index | 1 | 1999 | 377 | 0.010 |
Why?
|